An artificial intelligence (AI) program that aims to make it easier to identify bone metastases in men with prostate cancer has been granted 501(k) clearance by the U.S. Food and Drug Administration (FDA), its developer announced. The program uses a neural network — a type of AI — to identify hotspots on bone scans indicative of bone metastasis, which is when cancer cells spread from the prostate and start growing in bone tissue. It also calculates the…
You must be logged in to read/download the full post.
The post AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA appeared first on BioNewsFeeds.